

Apple Health PDL Drug Policy Motions

Androgenic Agents- Testosterone Replacement Therapy (TRT)

▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 23.10.00-2 as recommended.

▶ **Motion:** Lee

▶ **2nd:** Flatebo

Oncology: Radiopharmaceuticals (Lutathera®)

▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 21.60.00.45.20 as recommended.

▶ **Motion:** Flatebo

▶ **2nd:** Storhaug

Endocrine and Metabolic Agents- Revcovi™

▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 30.90.20.30-1 as recommended.

▶ **Motion:** Park

▶ **2nd:** Schwilke

Endocrine and Metabolic Agents: Metabolic Modifies- X-Linked Hypophosphatemia (Crysvita®)

▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 30.90.95-2 as recommended.

▶ **Motion: Park**

▶ **2nd: Brown**

Agents for ALS- Radicava®

- ▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 74.50.90-1 as recommended.
- ▶ Revisit reauthorization criteria. (2 or less?)
- ▶ Re-review in October

▶ **Motion:**

▶ **2nd:**

Ophthalmic Agents: Gene Therapy (Luxturna)

- ▶ **Motion:** I move that the Apple Health Medicaid Program implement the clinical criteria listed on policy 86.37.00-1 as recommended.
- ▶ Add back simultaneous steroid use.

▶ **Motion: Park**

▶ **2nd: Huynh**